Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Stock-Based Compensation Expense) (Details)

v3.24.1
Stockholders' Equity (Stock-Based Compensation Expense) (Details)
$ in Thousands
12 Months Ended
Aug. 10, 2023
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stockholders' Equity Note, Stock Split, Conversion Ratio 0.0667    
Stock-based compensation expense   $ 17,029 $ 22,987
Avenue Therapeutics, Inc [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense   907 649
Checkpoint [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense   2,897 2,924
Mustang      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense   567 2,283
Journey      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense   2,606 4,425
Other Partners [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense   107 54
Employee awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense   8,369 9,934
Executive awards      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Stock-based compensation expense   $ 1,576 $ 2,718